Ornithine Transcarbamylase (OTC) Deficiency

Ornithine transcarbamylase (OTC) deficiency is an X-linked genetic disorder of the urea cycle that leads to elevated levels of ammonia. OTC deficiency is the most common urea cycle disorder. The OTC enzyme is responsible for the condensation of carbamyl phosphate and ornithine to form citrulline. Reduced OTC enzymatic activity leads to diminished ammonia incorporation and consequent hyperammonemia (see Hyperammonemia). OTC is hepatically expressed and is intramitochondrial. ^[1]  The OTC gene is X-linked. To date, more than 500 disease-causing mutations have been reported (see the image below). ^{[2, 3]}

OTC accounts for approximately half of the urea cycle disorders. The estimated worldwide prevalence ranges from 1/113,000 to 1/56,500 live births. A peer-reviewed multi-country analysis compiling national/registry-derived estimates reported incidence approximations of 1 in 62,000 in Finland, 1 in 63,000 in the United States, and 1 in 69,904 in Italy, illustrating variability by country and ascertainment approach. ^{[4, 5]}

The Health Resources and Services Administration's newborn screening–oriented information provides a qualitative burden estimate, stating that "fewer than 300 babies are born with this condition each year in the United States," while also noting that confirmatory follow-up testing is required after out-of-range screening results. ^[6]

Because OTC deficiency is X-linked, severe neonatal-onset hyperammonemia is concentrated in hemizygous males, while heterozygous females demonstrate variable penetrance and can be asymptomatic or symptomatic depending partly on X-inactivation patterns. In the three-country (Turkey, France, and the United Kingdom) cohort audit, prevalent cohorts under follow-up were predominantly female, with males comprising roughly one third of patients (reported 33-38% across the audited national cohorts). In the same audit, patients presented with a neonatal-onset phenotype represented a minority of the followed patients (7-19% across countries), consistent with the large contribution of later-onset diagnoses and family-identified heterozygotes to prevalent clinic populations. ^[5]

OTC deficiency results from pathogenic variants in the OTC gene located on the X chromosome at  Xp21.1. The disorder follows X-linked inheritance. ^[3]

Over 500 distinct disease-causing mutations have been identified, with the majority being single-base substitutions, including missense, nonsense, and silent variants. Small deletions or insertions comprise approximately 12% of mutations, while large deletions account for approximately 4%. Frameshift mutations, splice-site errors, and regulatory mutations have also been documented. Most mutations are "private" (family-specific), with recurrent mutations occurring predominantly at CpG dinucleotide hotspots. ^[4] Novel mutations occurring spontaneously account for a proportion of cases, including father-to-daughter transmission in late-onset forms. ^{[7, 8]}

In individuals with partial enzyme deficiency, hyperammonemic crises can be precipitated by catabolic stressors, including infection, fever, fasting, surgery (particularly bariatric procedures), high protein intake, corticosteroid or nonsteroidal anti-inflammatory drug use, and the metabolic demands of pregnancy and peripartum period. ^[9]

Some clinically proven cases have no identifiable mutations on routine molecular testing; these may harbor large deletions, duplications, complex rearrangements, or mutations in the promoter and enhancer regions of the OTC gene. ^{[7, 8]}

OTC is a mitochondrial enzyme that catalyzes the condensation of carbamyl phosphate and ornithine to form citrulline, a critical proximal step in ureagenesis. ^[10]

Pathogenic variants in the OTC gene reduce or abolish enzyme activity, resulting in impaired citrulline synthesis and ureagenesis failure. Accumulation of carbamyl phosphate leads to its shunting into pyrimidine synthesis, causing secondary increases in orotic acid. The primary biochemical consequence is hyperammonemia, with elevated systemic ammonia and glutamine levels that are directly neurotoxic. ^[10]

In the central nervous system, ammonia disrupts astrocyte metabolism, induces intracellular glutamine accumulation, alters cerebral energy utilization, and promotes cytotoxic cerebral edema and neuronal injury. These biochemical abnormalities account for encephalopathy, seizures, and long-term neurocognitive sequelae across the phenotypic spectrum, from neonatal-onset to late-onset disease. The degree of residual OTC activity, influenced by genotype and X-chromosome inactivation patterns in heterozygous females, determines the clinical severity and age of onset. ^[10]

Morbidity and mortality are high, especially in patients with the neonatal form. Close follow-up with a metabolic center is essential for optimizing outcomes. As an X-linked trait, severity of presentation in heterozygous females is determined partly by skewed X-chromosome inactivation. In females, clinical severity may range from asymptomatic to severe, with a risk for life-threatening hyperammonemia.

The long-term prognosis for OTC deficiency varies significantly by phenotype but remains guarded regarding neurological function. For neonatal-onset cases, mortality approaches 90% without immediate intervention, and survivors are at high risk for intellectual disability. Neurological outcome correlates most strongly with the duration of hyperammonemic coma rather than the peak ammonia level; prolonged intracranial hypertension leads to irreversible cortical injury. ^[11]

In late-onset forms (including adults), the overall mortality rate is approximately 30%, with death often resulting from the initial unrecognized hyperammonemic crisis. For heterozygous females, clinical presentation is driven by the pattern of X-chromosome inactivation in hepatocytes. ^[12]

Female carriers who are clinically symptomatic may have significantly higher disease severity if they are carrying "severe" pathogenic variants. Even "asymptomatic" carriers frequently exhibit subclinical deficits in fine motor dexterity, executive function, and cognitive flexibility when challenged with complex neuropsychological tasks, despite preserved verbal intelligence. ^[13]

While liver transplantation effectively cures the metabolic defect and eliminates the need for dietary protein restriction, data from a multicenter study (published in 2023) indicate that it does not reverse preexisting neurodevelopmental deficits. Patients with established cognitive impairment prior to transplant typically demonstrate persisting difficulties in executive function and behavior post transplant. ^[14]